LeMaitre Vascular, Inc. reported a significant increase in financial performance for the third quarter of 2025, with net sales reaching $61.0 million, an 11% increase from $54.8 million in the same period last year. For the nine months ending September 30, 2025, net sales totaled $185.1 million, up 13% from $164.1 million in 2024. The company attributed this growth to higher average selling prices, increased unit volumes, and an expanded sales force. Gross profit for the quarter rose to $46.0 million, a 24% increase compared to $37.2 million in Q3 2024, with gross margins improving to 75.3% from 67.8% due to enhanced manufacturing efficiencies and a favorable product mix.
In terms of operational metrics, LeMaitre's sales force increased to 152 representatives as of September 30, 2025, reflecting a 4% growth year-over-year. The company also reported a favorable impact of $2.7 million from the Employee Retention Credit (ERC) during the quarter, which contributed significantly to the gross margin. The company’s inventory increased to $70.8 million from $64.9 million at the end of 2024, indicating a strategic buildup to support anticipated sales growth.
LeMaitre has been actively pursuing geographic expansion and product development. The company received multiple regulatory approvals for its products in various international markets, including the EU and Asia, which are expected to enhance its market presence. The company’s biologic products accounted for 54% of worldwide sales in Q3 2025, indicating a strong demand for these differentiated offerings. Additionally, the company has been transitioning from distributor sales to direct-to-hospital sales in several countries, which is anticipated to improve margins and customer relationships.
The company’s financial position remains strong, with cash and cash equivalents at $25.5 million and short-term marketable securities at $317.6 million as of September 30, 2025. LeMaitre's total assets increased to $598.1 million from $551.8 million at the end of 2024. The company has also authorized a stock repurchase program of up to $75 million, although no repurchases have been made to date. Looking ahead, LeMaitre plans to continue its focus on strategic acquisitions and expanding its direct sales force, while also managing costs and enhancing operational efficiencies to sustain growth in the competitive vascular device market.
About LEMAITRE VASCULAR INC
LeMaitre Vascular is a global provider of medical devices and human tissue cryopreservation services for treating vascular, renal, and cardiovascular diseases. Its product portfolio includes biologic patches, grafts, shunts, and surgical closure systems used primarily in open vascular surgeries. The company serves vascular surgeons and related specialists worldwide, leveraging a direct sales force and strategic acquisitions to maintain a competitive edge in niche markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.